Is Healthpeak Properties (DOC) Still Undervalued After A 38% Gain?

Healthpeak Properties has delivered a 3 year share price gain that may catch investors' attention, yet the key issue for a real estate investment trust like this is whether the current market value lines up with the cash it is expected to generate. With the stock recently closing at US$18.96, the question is how much of that move can be explained by the cash flows behind the business.

• Over the past 3 years, Healthpeak Properties has returned 38.0%, which puts the spotlight firmly on whether that share price journey is in step with the underlying cash flow profile.
• For a healthcare focused property owner that leans on rental income and asset disposals to fund operations and dividends, the outlook for stable occupancy, rent collection and capital spending plans can shape how reliable and timely those future cash flows really look.
• If you'd rather focus on earnings, this one's for you. See why Healthpeak Properties's 53.9x P/E tells a different valuation story.

The issue now is whether Healthpeak Properties' current US$18.96 share price is adequately supported by the cash flows implied by its intrinsic value estimate using a Discounted Cash Flow (DCF) approach.

If you are questioning whether Healthpeak Properties' US$18.96 share price is fairly anchored to its cash flows, you might also want to scan 33 high quality undervalued stocks.

Does Healthpeak Properties Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here uses Healthpeak Properties' adjusted funds from operations as a stand-in for equity cash flows. On that basis, the trust generated roughly $1.29b in free cash flow over the last twelve months, a level that gives the model a sizable base year to work from.

Analysts feeding into this framework are not assuming a rapid ramp up; instead, they project free cash flow staying in the same general ballpark and edging higher over the coming decade. When those projected cash streams are discounted back and stacked against today's US$18.96 share price, the DCF output points to an estimated intrinsic value that sits substantially above where the stock currently trades. Find out what Healthpeak Properties could be worth using our Discounted Cash Flow (DCF) estimate.

The Healthpeak Properties Narrative: What Would Justify Today's Price?

Narratives for Healthpeak Properties extend the valuation puzzle into clear scenarios that explain what would need to happen to future growth, earnings and margins for the stock to trade meaningfully above or below today's level, and they sit on Simply Wall St's Community page. Rather than relying on a single headline multiple or model output, each scenario sets out the assumptions behind its fair value so you can revisit those inputs as fresh results emerge.

Community views on Healthpeak Properties are split between a patient cash flow story and a more cautious read on execution risk and refinancing.

Bull case: 16% undervalued

"The current valuation implies that Healthpeak Properties' share price does not fully reflect the implied FFO yield above 10% on recent buybacks..."

Discover why this Narrative puts Healthpeak Properties at 16% undervalued.

Bear case: 6% overvalued

"Although Healthpeak Properties reports net debt to EBITDA of 4.7x and significant liquidity after repaying US$900 million of debt, the upcoming refinancing of US$650 million of senior notes that carried a roughly 3.5% coupon exposes the company to higher interest costs..."

Explore why this Narrative puts Healthpeak Properties at 6% overvalued.

One more Healthpeak Properties check that belongs beside the valuation work

Price and cash flows tell only part of the Healthpeak Properties story, because separate checks have flagged specific risk factors that deserve your attention before you lean on any valuation output. Take a closer look at 4 warning signs (2 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com